Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 102 entries
Sorted by: Best Match Show Resources per page
The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of .

Iranian journal of parasitology

Mahmoudvand H, Kheirandish F, Mirbadie SR, Kayedi MH, Rezaei Riabi T, Ghasemi AA, Bamorovat M, Sharifi I.
PMID: 28979343
Iran J Parasitol. 2017 Jul-Sep;12(3):339-347.

BACKGROUND: The present study aimed to evaluate the effect of methotrexate (MTX) alone and in combination with meglumine antimoniate (MA, Glucantime) against sensitive and MA-resistant METHODS: The present study was carried out in 2014 in Leishmaniasis Research Center at...

Cite
Mahmoudvand H, Kheirandish F, Mirbadie SR, et al. The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of . Iran J Parasitol. 2017;12(3):339-347
Mahmoudvand, H., Kheirandish, F., Mirbadie, S. R., Kayedi, M. H., Rezaei Riabi, T., Ghasemi, A. A., Bamorovat, M., & Sharifi, I. (2017). The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of . Iranian journal of parasitology, 12(3), 339-347.
Mahmoudvand, Hossein, et al. "The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of ." Iranian journal of parasitology vol. 12,3 (2017): 339-347.
Mahmoudvand H, Kheirandish F, Mirbadie SR, Kayedi MH, Rezaei Riabi T, Ghasemi AA, Bamorovat M, Sharifi I. The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of . Iran J Parasitol. 2017 Jul-Sep;12(3):339-347. PMID: 28979343; PMCID: PMC5623913.
Copy Download .nbib Format: NLM
First Report on Infant Acute Urticaria after Mother's Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report.

Iranian journal of public health

Mozafari O, Shorofi SA, Yousefi SS.
PMID: 27957467
Iran J Public Health. 2016 Sep;45(9):1217-1219.

Pentavalent antimonials are still the first drug of choice for the treatment of cutaneous leishmaniasis (CL). Like other treatments, they can cause adverse reactions including musculoskeletal pain, gastrointestinal disturbances, and mild to moderate headaches. In this paper, we report...

Cite
Mozafari O, Shorofi SA, Yousefi SS. First Report on Infant Acute Urticaria after Mother's Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report. Iran J Public Health. 2016;45(9):1217-1219
Mozafari, O., Shorofi, S. A., & Yousefi, S. S. (2016). First Report on Infant Acute Urticaria after Mother's Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report. Iranian journal of public health, 45(9), 1217-1219.
Mozafari, Omid, et al. "First Report on Infant Acute Urticaria after Mother's Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report." Iranian journal of public health vol. 45,9 (2016): 1217-1219.
Mozafari O, Shorofi SA, Yousefi SS. First Report on Infant Acute Urticaria after Mother's Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report. Iran J Public Health. 2016 Sep;45(9):1217-1219. PMID: 27957467; PMCID: PMC5149476.
Copy Download .nbib Format: NLM
Localized Bullous Eruption Away From Injection Site, Caused by Intramuscular Meglumine Antimoniate Administration.

The Annals of pharmacotherapy

Ben Salem C, Slim R, Fathallah N, Sriha B, Belajouza C.
PMID: 27048189
Ann Pharmacother. 2016 Jun;50(6):517-8. doi: 10.1177/1060028016641131. Epub 2016 Apr 05.

No abstract available.

Cite
Ben Salem C, Slim R, Fathallah N, et al. Localized Bullous Eruption Away From Injection Site, Caused by Intramuscular Meglumine Antimoniate Administration. Ann Pharmacother. 2016;50(6):517-8doi: 10.1177/1060028016641131.
Ben Salem, C., Slim, R., Fathallah, N., Sriha, B., & Belajouza, C. (2016). Localized Bullous Eruption Away From Injection Site, Caused by Intramuscular Meglumine Antimoniate Administration. The Annals of pharmacotherapy, 50(6), 517-8. https://doi.org/10.1177/1060028016641131
Ben Salem, Chaker, et al. "Localized Bullous Eruption Away From Injection Site, Caused by Intramuscular Meglumine Antimoniate Administration." The Annals of pharmacotherapy vol. 50,6 (2016): 517-8. doi: https://doi.org/10.1177/1060028016641131
Ben Salem C, Slim R, Fathallah N, Sriha B, Belajouza C. Localized Bullous Eruption Away From Injection Site, Caused by Intramuscular Meglumine Antimoniate Administration. Ann Pharmacother. 2016 Jun;50(6):517-8. doi: 10.1177/1060028016641131. Epub 2016 Apr 05. PMID: 27048189.
Copy Download .nbib Format: NLM
P-glycoprotein A Gene Expression in Glucantime-Resistant and Sensitive Leishmania major (MRHO/IR/75/ER).

Iranian journal of parasitology

Soleimanifard S, Arjmand R, Saberi S, Khamesipour A, Kazemi M, Salehi M, Akbari M, Hejazi S.
PMID: 25678928
Iran J Parasitol. 2014 Sep;9(3):423-8.

BACKGROUND: Leishmaniasis is a parasitic disease caused by different species of Leishmania parasites with a wide range of clinical manifestations. Antimonial compounds such as meglumine antimoniate (glucantime) are the first line drugs for the treatment of leishmaniasis. However, according...

Cite
Soleimanifard S, Arjmand R, Saberi S, et al. P-glycoprotein A Gene Expression in Glucantime-Resistant and Sensitive Leishmania major (MRHO/IR/75/ER). Iran J Parasitol. 2014;9(3):423-8
Soleimanifard, S., Arjmand, R., Saberi, S., Khamesipour, A., Kazemi, M., Salehi, M., Akbari, M., & Hejazi, S. (2014). P-glycoprotein A Gene Expression in Glucantime-Resistant and Sensitive Leishmania major (MRHO/IR/75/ER). Iranian journal of parasitology, 9(3), 423-8.
Soleimanifard, Simindokht, et al. "P-glycoprotein A Gene Expression in Glucantime-Resistant and Sensitive Leishmania major (MRHO/IR/75/ER)." Iranian journal of parasitology vol. 9,3 (2014): 423-8.
Soleimanifard S, Arjmand R, Saberi S, Khamesipour A, Kazemi M, Salehi M, Akbari M, Hejazi S. P-glycoprotein A Gene Expression in Glucantime-Resistant and Sensitive Leishmania major (MRHO/IR/75/ER). Iran J Parasitol. 2014 Sep;9(3):423-8. PMID: 25678928; PMCID: PMC4316575.
Copy Download .nbib Format: NLM
Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis.

Dermatology research and practice

Yazdanpanah MJ, Banihashemi M, Pezeshkpoor F, Khajedaluee M, Famili S, Tavakoli Rodi I, Yousefzadeh H.
PMID: 21747837
Dermatol Res Pract. 2011;2011:269515. doi: 10.1155/2011/269515. Epub 2011 Jul 06.

The purpose of this study was to investigate comparison between oral zinc sulfate and meglumine antimoniate in the treatment of cutaneous leishmaniasis (CL). So 100 patients with CL were included and randomly divided into two groups. The first group...

Cite
Yazdanpanah MJ, Banihashemi M, Pezeshkpoor F, et al. Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis. Dermatol Res Pract. 2011;2011:269515doi: 10.1155/2011/269515.
Yazdanpanah, M. J., Banihashemi, M., Pezeshkpoor, F., Khajedaluee, M., Famili, S., Tavakoli Rodi, I., & Yousefzadeh, H. (2011). Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis. Dermatology research and practice, 2011269515. https://doi.org/10.1155/2011/269515
Yazdanpanah, Mohamad Javad, et al. "Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis." Dermatology research and practice vol. 2011 (2011): 269515. doi: https://doi.org/10.1155/2011/269515
Yazdanpanah MJ, Banihashemi M, Pezeshkpoor F, Khajedaluee M, Famili S, Tavakoli Rodi I, Yousefzadeh H. Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis. Dermatol Res Pract. 2011;2011:269515. doi: 10.1155/2011/269515. Epub 2011 Jul 06. PMID: 21747837; PMCID: PMC3130957.
Copy Download .nbib Format: NLM
Treatment of cutaneous lesion of 20 years' duration caused by leishmanization.

Indian journal of dermatology

Khamesipour A, Abbasi A, Firooz A, Mohammadi AM, Eskandari SE, Jaafari MR.
PMID: 22615509
Indian J Dermatol. 2012 Mar;57(2):123-5. doi: 10.4103/0019-5154.94280.

The inoculation of live Leishmania (L.) major to produce a single lesion is called leishmanization (LZ). LZ lesion upon cure prevents further natural infection which might be multiple lesions on unwanted sites such as face. Cutaneous leishmaniasis (CL) usually...

Cite
Khamesipour A, Abbasi A, Firooz A, et al. Treatment of cutaneous lesion of 20 years' duration caused by leishmanization. Indian J Dermatol. 2012;57(2):123-5doi: 10.4103/0019-5154.94280.
Khamesipour, A., Abbasi, A., Firooz, A., Mohammadi, A. M., Eskandari, S. E., & Jaafari, M. R. (2012). Treatment of cutaneous lesion of 20 years' duration caused by leishmanization. Indian journal of dermatology, 57(2), 123-5. https://doi.org/10.4103/0019-5154.94280
Khamesipour, Ali, et al. "Treatment of cutaneous lesion of 20 years' duration caused by leishmanization." Indian journal of dermatology vol. 57,2 (2012): 123-5. doi: https://doi.org/10.4103/0019-5154.94280
Khamesipour A, Abbasi A, Firooz A, Mohammadi AM, Eskandari SE, Jaafari MR. Treatment of cutaneous lesion of 20 years' duration caused by leishmanization. Indian J Dermatol. 2012 Mar;57(2):123-5. doi: 10.4103/0019-5154.94280. PMID: 22615509; PMCID: PMC3352634.
Copy Download .nbib Format: NLM
Antileishmanial Activity of .

Iranian journal of parasitology

Shokri A, Saeedi M, Fakhar M, Morteza-Semnani K, Keighobadi M, Hosseini Teshnizi S, Kelidari HR, Sadjadi S.
PMID: 29317888
Iran J Parasitol. 2017 Oct-Dec;12(4):622-631.

BACKGROUND: The aim of present study was to evaluate antileishmanial effects of METHODS: The present study was performed in Leishmaniasis Reference Lab at Mazandaran University of Medical Sciences, Iran during 2016-2017. The IC50 values were calculated in both the...

Cite
Shokri A, Saeedi M, Fakhar M, et al. Antileishmanial Activity of . Iran J Parasitol. 2017;12(4):622-631
Shokri, A., Saeedi, M., Fakhar, M., Morteza-Semnani, K., Keighobadi, M., Hosseini Teshnizi, S., Kelidari, H. R., & Sadjadi, S. (2017). Antileishmanial Activity of . Iranian journal of parasitology, 12(4), 622-631.
Shokri, Azar, et al. "Antileishmanial Activity of ." Iranian journal of parasitology vol. 12,4 (2017): 622-631.
Shokri A, Saeedi M, Fakhar M, Morteza-Semnani K, Keighobadi M, Hosseini Teshnizi S, Kelidari HR, Sadjadi S. Antileishmanial Activity of . Iran J Parasitol. 2017 Oct-Dec;12(4):622-631. PMID: 29317888; PMCID: PMC5756313.
Copy Download .nbib Format: NLM
Anti-Leishmanial and Immunomodulatory Effects of Epigallocatechin 3-O-Gallate on .

Iranian journal of parasitology

Saduqi M, Sharifi I, Babaei Z, Keyhani A, Mostafavi M, Hakimi Parizi M, Ghasemian M, Bamorovat M, Sharifi F, Aflatoonian MR, Sharififar F, Ghasemi Nejad P, Khosravi A, Salarkia E, Varma RS.
PMID: 32099555
Iran J Parasitol. 2019 Oct-Dec;14(4):521-533.

BACKGROUND: Pentavalent antimonials such as meglumine antimoniate (MA, Glucantime), are the first-line treatment against leishmaniasis, but at present, they have basically lost their efficacy. This study was aimed to explore epigallocatechin 3-O-gallate (EGCG), alone or in combination with MA...

Cite
Saduqi M, Sharifi I, Babaei Z, et al. Anti-Leishmanial and Immunomodulatory Effects of Epigallocatechin 3-O-Gallate on . Iran J Parasitol. 2019;14(4):521-533
Saduqi, M., Sharifi, I., Babaei, Z., Keyhani, A., Mostafavi, M., Hakimi Parizi, M., Ghasemian, M., Bamorovat, M., Sharifi, F., Aflatoonian, M. R., Sharififar, F., Ghasemi Nejad, P., Khosravi, A., Salarkia, E., & Varma, R. S. (2019). Anti-Leishmanial and Immunomodulatory Effects of Epigallocatechin 3-O-Gallate on . Iranian journal of parasitology, 14(4), 521-533.
Saduqi, Morteza, et al. "Anti-Leishmanial and Immunomodulatory Effects of Epigallocatechin 3-O-Gallate on ." Iranian journal of parasitology vol. 14,4 (2019): 521-533.
Saduqi M, Sharifi I, Babaei Z, Keyhani A, Mostafavi M, Hakimi Parizi M, Ghasemian M, Bamorovat M, Sharifi F, Aflatoonian MR, Sharififar F, Ghasemi Nejad P, Khosravi A, Salarkia E, Varma RS. Anti-Leishmanial and Immunomodulatory Effects of Epigallocatechin 3-O-Gallate on . Iran J Parasitol. 2019 Oct-Dec;14(4):521-533. PMID: 32099555; PMCID: PMC7028242.
Copy Download .nbib Format: NLM
Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis.

Pharmaceutics

Berenguer D, Sosa L, Alcover M, Sessa M, Halbaut L, Guillén C, Fisa R, Calpena-Campmany AC, Riera C.
PMID: 31731660
Pharmaceutics. 2019 Nov 15;11(11). doi: 10.3390/pharmaceutics11110613.

Cutaneous leishmaniasis (CL) is treated with painful intralesional injections of meglumine antimoniate (MA). With the aim of developing an alternative topical treatment for CL, a gel-based formulation with 30% MA was prepared and its physicochemical properties, stability and rheological...

Cite
Berenguer D, Sosa L, Alcover M, et al. Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis. Pharmaceutics. 2019;11(11)doi: 10.3390/pharmaceutics11110613.
Berenguer, D., Sosa, L., Alcover, M., Sessa, M., Halbaut, L., Guillén, C., Fisa, R., Calpena-Campmany, A. C., & Riera, C. (2019). Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis. Pharmaceutics, 11(11), . https://doi.org/10.3390/pharmaceutics11110613
Berenguer, Diana, et al. "Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis." Pharmaceutics vol. 11,11 (2019). doi: https://doi.org/10.3390/pharmaceutics11110613
Berenguer D, Sosa L, Alcover M, Sessa M, Halbaut L, Guillén C, Fisa R, Calpena-Campmany AC, Riera C. Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis. Pharmaceutics. 2019 Nov 15;11(11). doi: 10.3390/pharmaceutics11110613. PMID: 31731660; PMCID: PMC6920791.
Copy Download .nbib Format: NLM
Meglumine Antimoniate-Loaded Aqueous-Core PLA Nanocapsules: Old Drug, New Formulation against Leishmania-Related Diseases.

Macromolecular bioscience

Cosco D, Bruno F, Castelli G, Puleio R, Bonacci S, Procopio A, Britti D, Fresta M, Vitale F, Paolino D.
PMID: 34117834
Macromol Biosci. 2021 Jul;21(7):e2100046. doi: 10.1002/mabi.202100046. Epub 2021 Jun 12.

Leishmaniasis is a human and animal disease endemic in tropical and subtropical areas treated by means of pentavalent antimony as first-line approach. Unfortunately, the formulations available on the market are characterized by significant side effects and a total remission...

Cite
Cosco D, Bruno F, Castelli G, et al. Meglumine Antimoniate-Loaded Aqueous-Core PLA Nanocapsules: Old Drug, New Formulation against Leishmania-Related Diseases. Macromol Biosci. 2021;21(7):e2100046doi: 10.1002/mabi.202100046.
Cosco, D., Bruno, F., Castelli, G., Puleio, R., Bonacci, S., Procopio, A., Britti, D., Fresta, M., Vitale, F., & Paolino, D. (2021). Meglumine Antimoniate-Loaded Aqueous-Core PLA Nanocapsules: Old Drug, New Formulation against Leishmania-Related Diseases. Macromolecular bioscience, 21(7), e2100046. https://doi.org/10.1002/mabi.202100046
Cosco, Donato, et al. "Meglumine Antimoniate-Loaded Aqueous-Core PLA Nanocapsules: Old Drug, New Formulation against Leishmania-Related Diseases." Macromolecular bioscience vol. 21,7 (2021): e2100046. doi: https://doi.org/10.1002/mabi.202100046
Cosco D, Bruno F, Castelli G, Puleio R, Bonacci S, Procopio A, Britti D, Fresta M, Vitale F, Paolino D. Meglumine Antimoniate-Loaded Aqueous-Core PLA Nanocapsules: Old Drug, New Formulation against Leishmania-Related Diseases. Macromol Biosci. 2021 Jul;21(7):e2100046. doi: 10.1002/mabi.202100046. Epub 2021 Jun 12. PMID: 34117834.
Copy Download .nbib Format: NLM
Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis.

Molecular immunology

Cardoso JMO, Brito RCF, Mathias FAS, Reis LES, Vieira JFP, Ostolin TLVDP, Andrade HM, Ramos GS, Frézard F, Aguiar-Soares RDO, Roatt BM, Reis AB.
PMID: 34814056
Mol Immunol. 2021 Nov 20;141:70-78. doi: 10.1016/j.molimm.2021.11.011. Epub 2021 Nov 20.

This study compared the therapeutic potential of the chemotherapy using meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes (Nano Sb

Cite
Cardoso JMO, Brito RCF, Mathias FAS, et al. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis. Mol Immunol. 2021;141:70-78doi: 10.1016/j.molimm.2021.11.011.
Cardoso, J. M. O., Brito, R. C. F., Mathias, F. A. S., Reis, L. E. S., Vieira, J. F. P., Ostolin, T. L. V. D. P., Andrade, H. M., Ramos, G. S., Frézard, F., Aguiar-Soares, R. D. O., Roatt, B. M., & Reis, A. B. (2021). Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis. Molecular immunology, 14170-78. https://doi.org/10.1016/j.molimm.2021.11.011
Cardoso, Jamille Mirelle de Oliveira, et al. "Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis." Molecular immunology vol. 141 (2021): 70-78. doi: https://doi.org/10.1016/j.molimm.2021.11.011
Cardoso JMO, Brito RCF, Mathias FAS, Reis LES, Vieira JFP, Ostolin TLVDP, Andrade HM, Ramos GS, Frézard F, Aguiar-Soares RDO, Roatt BM, Reis AB. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis. Mol Immunol. 2021 Nov 20;141:70-78. doi: 10.1016/j.molimm.2021.11.011. Epub 2021 Nov 20. PMID: 34814056.
Copy Download .nbib Format: NLM
Outbreak of Cutaneous Leishmaniasis among military personnel in French Guiana, 2020: Clinical, phylogenetic, individual and environmental aspects.

PLoS neglected tropical diseases

Henry K, Mayet A, Hernandez M, Frechard G, Blanc PA, Schmitt M, André N, Loreau JM, Ginouves M, Prévot G, Couppié P, Demar M, Blaizot R.
PMID: 34797836
PLoS Negl Trop Dis. 2021 Nov 19;15(11):e0009938. doi: 10.1371/journal.pntd.0009938. eCollection 2021 Nov.

BACKGROUND: Cutaneous Leishmaniasis (CL) is endemic in French Guiana but cases are usually sporadic. An outbreak signal was issued on May 15th 2020 with 15 suspected cases after a military training course in the rainforest. An outbreak investigation was...

Cite
Henry K, Mayet A, Hernandez M, et al. Outbreak of Cutaneous Leishmaniasis among military personnel in French Guiana, 2020: Clinical, phylogenetic, individual and environmental aspects. PLoS Negl Trop Dis. 2021;15(11):e0009938doi: 10.1371/journal.pntd.0009938.
Henry, K., Mayet, A., Hernandez, M., Frechard, G., Blanc, P. A., Schmitt, M., André, N., Loreau, J. M., Ginouves, M., Prévot, G., Couppié, P., Demar, M., & Blaizot, R. (2021). Outbreak of Cutaneous Leishmaniasis among military personnel in French Guiana, 2020: Clinical, phylogenetic, individual and environmental aspects. PLoS neglected tropical diseases, 15(11), e0009938. https://doi.org/10.1371/journal.pntd.0009938
Henry, Kim, et al. "Outbreak of Cutaneous Leishmaniasis among military personnel in French Guiana, 2020: Clinical, phylogenetic, individual and environmental aspects." PLoS neglected tropical diseases vol. 15,11 (2021): e0009938. doi: https://doi.org/10.1371/journal.pntd.0009938
Henry K, Mayet A, Hernandez M, Frechard G, Blanc PA, Schmitt M, André N, Loreau JM, Ginouves M, Prévot G, Couppié P, Demar M, Blaizot R. Outbreak of Cutaneous Leishmaniasis among military personnel in French Guiana, 2020: Clinical, phylogenetic, individual and environmental aspects. PLoS Negl Trop Dis. 2021 Nov 19;15(11):e0009938. doi: 10.1371/journal.pntd.0009938. eCollection 2021 Nov. PMID: 34797836; PMCID: PMC8641862.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 102 entries